Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/8/2025

Treatment of Hypomania/Mania with FDA-Approved Medications

First-Line Treatment Options

  • The American Academy of Child and Adolescent Psychiatry recommends using FDA-approved medications, such as lithium, aripiprazole, valproate, olanzapine, risperidone, quetiapine, and ziprasidone, as first-line treatments for acute mania or hypomania in bipolar disorder 1, 2
  • Lithium is approved for acute mania and maintenance therapy in patients aged 12 and above 1
  • Aripiprazole, valproate, olanzapine, risperidone, quetiapine, and ziprasidone are approved for acute mania in adults 1

Treatment Algorithm for Hypomania/Mania

  • The initial assessment should determine if the presentation is bipolar I mania, bipolar II hypomania, or mixed features, and first-line treatment should be based on this assessment 1, 2
  • For well-defined bipolar I mania, first-line treatment options include lithium, valproate, or an FDA-approved atypical antipsychotic (aripiprazole, olanzapine, risperidone, quetiapine, ziprasidone) 1, 2

Monitoring and Safety Considerations

  • When using atypical antipsychotics, monitor patients for weight gain and metabolic issues, such as diabetes and hyperlipidemia 5
  • Baseline and follow-up assessments of BMI, waist circumference, blood pressure, fasting glucose, and lipid panel are recommended when using atypical antipsychotics 5
  • Extrapyramidal symptoms and tardive dyskinesia should also be monitored when using atypical antipsychotics 5
  • Antidepressants, such as SSRIs, should be used with caution in patients with bipolar disorder due to the risk of triggering manic episodes 1, 2, 3

REFERENCES